Prostaglandin E1 reduces the frequency of rejection after heart transplantation.
This retrospective study was carried out to evaluate the effect of prostaglandin E1 on the frequency of rejection in 36 heart transplant recipients who survived orthotopic heart transplantation for 60 days or longer. The therapy for both groups was the same except group 1 (n = 12) was given PGE1 for 6 to 14 days. Indication for the PGE1 was right ventricular mismatch or failure. The prostaglandin administration started during the transplantation procedure. The dosage was 28 to 64 ng/kg/min and was tapered down from 14.7 to 32 ng later. No major side effects related to PGE1 have been observed. During the first 60 days after heart transplantation, in the group treated with prostaglandin, rejection grade 2 or higher was evident in 0.91 biopsies/patient versus 2.2 in nontreated patients, (p less than 0.05). A prolonged interval free from rejection (p less than 0.05) was observed in the patients treated with prostaglandin.
Iberer
F
F
Department of Transplantation, University of Graz, Austria.
Wasler
A
A
Tscheliessnigg
K
K
Vujicic
R
R
Rehak
P
P
Giegerl
E
E
Popper
H H
HH
Kleinert
R
R
Berger
J
J
Auer
T
T
D000527:Alprostadil / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D016027:Heart Transplantation / Q000276:immunology* / Q000706:statistics & numerical data; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D000527:Alprostadil